NCT03473444

Brief Summary

The prevalence of hyperuricemia has rarely been investigated in developing countries Hyperuricemia, or raised serum uric acid (SUA), is the condition closely associated with gout due to the deposition of monosodium urate crystals in peripheral joints and soft tissues. Hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors. This risk appears more pronounced in younger individuals and women. Cross-sectional studies show an association of hyperuricemia with the presence of CKD. Insulin resistance plays a potentially key role in the causal relationship between metabolic syndrome, type 2 Diabetes and hyperuricemia. Furthermore, it is likely that hyperuricemia and insulin resistance share a bidirectional causal effect. The rationale of this study is to determine prevalence of hyperuricemia in Pakistan.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2018

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

March 15, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 22, 2018

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2018

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2018

Completed
Last Updated

March 22, 2018

Status Verified

March 1, 2018

Enrollment Period

1 month

First QC Date

March 15, 2018

Last Update Submit

March 15, 2018

Conditions

Keywords

uric acidprevalencepakistan

Outcome Measures

Primary Outcomes (1)

  • Prevalence of Hyperuricemia

    To find out the frequency uric acid levels in Pakistani general population

    4 weeks

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Informed consent was obtained from all patients and their attendant coming to clinics. Those who agreed to be part of this study were asked a questionnaire about co-morbidity and symptoms. Uric acid levels were assessed by using UASure Blood Uric Acid Monitoring System. Male with uric acid levels greater than 7 mg/dl and female greater than 6 mg/dl were classified as hyperuricemia.

You may qualify if:

  • Informed Consent given

You may not qualify if:

  • No Informed consent provided

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr. Abid Naeem

Mirpur, Azad Kashmir, Pakistan

RECRUITING

MeSH Terms

Conditions

Hyperuricemia

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2018

First Posted

March 22, 2018

Study Start

March 1, 2018

Primary Completion

April 1, 2018

Study Completion

April 15, 2018

Last Updated

March 22, 2018

Record last verified: 2018-03

Data Sharing

IPD Sharing
Will not share

Locations